<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229004</url>
  </required_header>
  <id_info>
    <org_study_id>PanCAN_Precision Promise</org_study_id>
    <nct_id>NCT04229004</nct_id>
  </id_info>
  <brief_title>A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer</brief_title>
  <official_title>Precision Promise Platform Trial for Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pancreatic Cancer Action Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pancreatic Cancer Action Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate&#xD;
      multiple regimens in metastatic pancreatic cancer.&#xD;
&#xD;
      Primary Objectives&#xD;
&#xD;
        -  To compare each investigational arm versus standard of care (SOC) for superiority in&#xD;
           overall survival in 1st and/or 2nd line metastatic pancreatic cancer patients and&#xD;
           determine which, if any, patients benefit from each investigational arm.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        -  To determine short and long-term safety signals of each investigational arm in&#xD;
           pancreatic cancer patients vs. SOC.&#xD;
&#xD;
        -  To determine progression-free survival (PFS) for each investigational arm vs. SOC.&#xD;
&#xD;
        -  Rates of overall response, CR, and PR; duration of overall response, CR or PR (whichever&#xD;
           occurs first).&#xD;
&#xD;
        -  Rate of clinical benefit; duration of clinical benefit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate&#xD;
      multiple regimens in metastatic pancreatic cancer. The goal of the platform is to find&#xD;
      effective therapies for pancreatic cancer. The platform will rapidly and efficiently test&#xD;
      multiple novel drugs and combinations compared to standard of care therapy in first and&#xD;
      second metastatic patients. Bayesian response-adaptive randomization will be used to assign&#xD;
      patients to arms based on their performance in subtypes of the disease. The primary endpoint&#xD;
      is overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2020</start_date>
  <completion_date type="Anticipated">February 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>0 weeks</time_frame>
    <description>Overall survival (OS) is defined from the time of initiation of treatment until death due to any cause. Subjects still alive at the time of an analysis will be considered censored at their date of last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From initiation of therapy to clinically determined disease progression or death due to any cause, whichever came first, assessed up to 24 months.</time_frame>
    <description>PFS will be presented with probability that the hazard ratio is less than 1.0 as well as the corresponding Kaplan-Meier curves and the log-rank test for the comparison with controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Status</measure>
    <time_frame>From screening through study completion, an average of 2 years.</time_frame>
    <description>Changes in Performance Status will be evaluated using the Eastern Cooperative Oncology Group (ECOG) Performance Status, where the highest value is 0 (patient is fully active) and the lowest value is 5 (patient is deceased).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>From initiation of treatment to clinically determined tumor size reduction for a minimum of 4 weeks</time_frame>
    <description>ORR is defined as the portion of subjects on an arm with a tumor size reduction of at least 30%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Response Rate (ORR)</measure>
    <time_frame>From date of first occurrence of a documented objective response to date of clinically determined disease progression or death due to any cause, whichever came first, assessed up to 24 months.</time_frame>
    <description>Duration of ORR is defined as the time from the date of response to the date of clinically determined disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Clinical Benefit</measure>
    <time_frame>From screening through last dose of therapy, assessed up to 24 months.</time_frame>
    <description>Duration of Clinical Benefit will be evaluated using a composite of measures including patient reported outcomes (PROs), supportive care regimens, and disease status.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">825</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Gemcitabine combined with nab-paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted as long as drug dosing and modification guidelines are followed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SM-88</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus.&#xD;
All four agents (SM-88, methoxsalen, phenytoin, and sirolimus) should be dosed with approximately 240 mL (8 fl. oz.) of water in the morning. All four agents should be taken together consistently. SM-88 used with MPS should ideally be taken approximately 1 hour before or 2 hours after a meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFIRINOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxaliplatin 85 mg/m2, Leucovorin 400 mg/m2, Irinotecan 150 mg/m2, 5-Fluorouracil 2400 mg/m2 46-48 hour infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pamrevlumab (FibroGen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Pamrevlumab in combination with gemcitabine/nab-paclitaxel.&#xD;
Subjects enrolled to this treatment arm will receive treatment with pamrevlumab in combination with gemcitabine and nab-paclitaxel.&#xD;
Gemcitabine and nab-paclitaxel are FDA approved therapies for metastatic pancreatic cancer and will be supplied or obtained according to local clinical study agreements and in accordance with local guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine combined with nab-paclitaxel</intervention_name>
    <description>Nab-paclitaxel is infused over 30-40 min on days 1, 8, 15 of each 28-day cycle. Gemcitabine is infused over 30 min, immediately after completion of nab-paclitaxel infusion, on days 1, 8, 15 of each 28-day cycle If one of the chemotherapy medications is held, the other study medications may be given.&#xD;
Doses should be re-adjusted if the subject's BSA changes by +/- &gt;10%. If the subject's BSA changes by &lt;10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current BSA according to institutional guidelines.</description>
    <arm_group_label>Gemcitabine combined with nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose -SM-88</intervention_name>
    <description>460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus.</description>
    <arm_group_label>SM-88</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose -mFOLFIRINOX</intervention_name>
    <description>The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted, as long as drug dosing and modification guidelines are followed. Oxaliplatin and leucovorin are administered concurrently over 30-120 minutes, followed by irinotecan over 30-90 minutes, followed by the infusion of 5-flurouracil. If one of the chemotherapy medications is held, the other study medications may be given. Doses should be re-adjusted if the subject's BSA changes by +/- &gt;10%. If the subject's BSA changes by &lt;10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current BSA according to institutional guidelines.</description>
    <arm_group_label>mFOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose</intervention_name>
    <description>Pamrevlumab 35mg/kg IV - Day 1, 15 with an additional dose on Day 8 of Cycle 1 only&#xD;
Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15&#xD;
Gemcitabine 1000mg/m2 IV - Day 1, 8, 15</description>
    <arm_group_label>pamrevlumab (FibroGen)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A subject will be eligible to participate in Precision PromiseSM if all the below inclusion&#xD;
        criteria are met:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma (PDAC)&#xD;
             and eligible for treatment in the first line or second line settings. Note: prior&#xD;
             adjuvant or neoadjuvant chemotherapy is permitted if the last dose was &gt;12 months&#xD;
             prior and all the other conditions below are met.&#xD;
&#xD;
          3. Radiographically measurable disease of at least one site by computed tomography (CT)&#xD;
             scan (or magnetic resonance imaging, if allergic to CT contrast media) as defined by&#xD;
             Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Imaging results must be&#xD;
             obtained within the 28-day window, prior to randomization.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          5. Adequate organ function (lab results must be obtained within the 28-day window prior&#xD;
             to randomization)&#xD;
&#xD;
               1. Absolute neutrophil count ≥ 1500/mm3&#xD;
&#xD;
               2. Hemoglobin ≥ the lower limit of normal (LLN) or 9g/dL&#xD;
&#xD;
               3. Platelets ≥ 100,000/mm&#xD;
&#xD;
               4. Serum creatinine ≤ 1.0 x upper limit normal (ULN), or calculated creatinine&#xD;
                  clearance ≥ 60 mL/min (Cockcroft Gault)&#xD;
&#xD;
               5. Albumin ≥ 3.0 g/dL&#xD;
&#xD;
               6. Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT)&#xD;
                  and/or alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT)&#xD;
                  ≤ 2.5 x ULN (up to 5 x ULN in presence of liver metastasis).&#xD;
&#xD;
               7. Total bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               8. INR ≤ 1.5 x ULN&#xD;
&#xD;
          6. Consent to provide protocol-mandated tissue and blood samples for diagnostic and&#xD;
             research purposes.&#xD;
&#xD;
          7. Able to swallow pills, capsules or tablets.&#xD;
&#xD;
          8. Able to adhere to study visit schedule and other protocol requirements.&#xD;
&#xD;
          9. Females of childbearing potential [defined as a sexually mature woman who (1) has not&#xD;
             undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy&#xD;
             (the surgical removal of both ovaries) or (2) has not been naturally postmenopausal&#xD;
             for at least 24 consecutive months (i.e., has had menses at any time during the&#xD;
             preceding 24 consecutive months)] must:&#xD;
&#xD;
               1. Have a negative serum or urine pregnancy test (β-human chorionic gonadotropin&#xD;
                  [β-hCG]) as verified by the study doctor within 14 days prior to randomization.&#xD;
&#xD;
               2. Commit to complete abstinence from heterosexual contact or agree to use medical&#xD;
                  doctor-approved contraception throughout the study without interruption while&#xD;
                  receiving study treatment and for at least 6 months following last dose of study&#xD;
                  treatment.&#xD;
&#xD;
         10. Males must practice complete abstinence or agree to use a condom (even if he has&#xD;
             undergone a successful vasectomy) during sexual contact with a pregnant female or a&#xD;
             female of childbearing potential while participating in the study, during dose&#xD;
             interruptions and for at least 6 months following last dose of study treatment.&#xD;
&#xD;
         11. Understands the nature of the study and has agreed to participate by voluntarily&#xD;
             signing the IRB approved informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A subject will not be eligible to participate in Precision PromiseSM if any of the&#xD;
             following criteria are met:&#xD;
&#xD;
             a) Received any therapy within 28 days (or 5 half-lives, whichever is shorter,) prior&#xD;
             to randomization.&#xD;
&#xD;
          2. History of allergy or hypersensitivity to any of the study treatments or any of their&#xD;
             excipients.&#xD;
&#xD;
          3. Pre-existing peripheral neuropathy &gt; Grade 1, as defined by CTCAE V 4.03.&#xD;
&#xD;
          4. Known history of hepatitis B, HIV or active hepatitis C infection.&#xD;
&#xD;
          5. Note: HIV testing is not required in the absence of clinical suspicion&#xD;
&#xD;
          6. Serious, non-healing wound, ulcer, bone fracture, or abscess.&#xD;
&#xD;
          7. The inability to swallow pills, capsules or tablets.&#xD;
&#xD;
          8. Subjects who received a combination of two investigational agents as part of&#xD;
             first-line therapy (novel + novel) are excluded. Subjects who received one&#xD;
             investigational agent or one investigational agent combined with an FDA approved&#xD;
             chemotherapy regimen in first line will be allowed to be enrolled in Precision&#xD;
             PromiseSM for second line therapy.&#xD;
&#xD;
          9. Any secondary malignancy that required chemotherapy treatment in the past two years&#xD;
&#xD;
         10. History of interstitial lung disease, history of slowly progressive dyspnea and&#xD;
             unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary&#xD;
             hypersensitivity pneumonitis or multiple allergies.&#xD;
&#xD;
         11. QTc &gt; 450 msec if male and QTc &gt; 470 msec if female.&#xD;
&#xD;
         12. Uncontrolled or severe cardiac disease (history of unstable angina, myocardial&#xD;
             infarction, coronary stenting, or bypass surgery within the prior 6 months),&#xD;
             symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia&#xD;
             [including atrial flutter/fibrillation], requirement for inotropic support or use of&#xD;
             devices for cardiac conditions [pacemakers/defibrillators]).&#xD;
&#xD;
         13. Active, uncontrolled infections (bacterial, viral, or fungal infection(s)) requiring&#xD;
             systemic therapy, defined as ongoing signs/symptoms related to the infection without&#xD;
             improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment&#xD;
             (i.e., subjects must be afebrile for &gt; 48 hours off antibiotics).&#xD;
&#xD;
         14. Active, known or suspected autoimmune disease, including systemic lupus erythematosus,&#xD;
             Hashimotos thyroiditis, scleroderma, polyarteritis nodosa or autoimmune hepatitis.&#xD;
&#xD;
             a) Subjects with type I diabetes mellitus, hypothyroidism requiring only hormone&#xD;
             replacement, skin disorders (such as vitiligo, psoriasis or alopecia) not requiring&#xD;
             systemic treatment, or conditions not expected to recur in the absence of an external&#xD;
             trigger are eligible to participate.&#xD;
&#xD;
         15. Receiving immunosuppressive or myelosuppressive medications that would, in the opinion&#xD;
             of the Investigator, increase the risk of serious neutropenic complications.&#xD;
&#xD;
         16. Receipt of live vaccines within 30 days prior to the first dose of study treatment or&#xD;
             while on active treatment within the trial. (examples of live vaccines include, but&#xD;
             are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever,&#xD;
             rabies, BCG, and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are&#xD;
             generally killed virus vaccines and are permitted. However, intranasal influenza&#xD;
             vaccines (e.g. Flu-Mist are live attenuated vaccines and are not permitted).&#xD;
&#xD;
         17. Any significant medical condition, laboratory abnormality or psychiatric illness that&#xD;
             would limit the subject's ability to comply with study requirements.&#xD;
&#xD;
         18. Subjects that discontinued previous treatment for pancreatic adenocarcinoma due to a&#xD;
             treatment-related Grade 3 toxicity.&#xD;
&#xD;
               1. For toxicity discontinuations &lt; Grade 3, AE(s) must resolve to Grade 1 or&#xD;
                  baseline in order to be considered eligible for this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, San Diego (UCSD) - Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maribel Felix</last_name>
      <phone>858-246-0791</phone>
      <email>mdfelix@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Aaron Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048-1804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruby Langeslay</last_name>
      <phone>310-967-0695</phone>
      <email>ruby.langeslay@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Brian Minton</last_name>
      <phone>310-967-0695</phone>
      <email>brian.minton@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Hendifar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Milloy</last_name>
      <phone>415-502-3310</phone>
      <email>alexandra.milloy@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Ko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrystal Bailey</last_name>
      <phone>352-265-0680</phone>
      <phone_ext>58003</phone_ext>
      <email>cbailey1@ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Margaret Veal</last_name>
      <phone>352-265-0680</phone>
      <email>mamcewan@ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas J George</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamika Harris</last_name>
      <phone>773-702-4367</phone>
      <email>tharris@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Hedy Kindler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosalind Walker, RN</last_name>
      <phone>410-955-9628</phone>
      <email>rwalker3@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
      <phone>410-614-3644</phone>
      <email>ssartor1@jh.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Laheru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Vincitore</last_name>
      <phone>617-632-3125</phone>
      <email>michele_vincitore@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Wolpin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - Washington University Medical Campus</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Boice</last_name>
      <phone>314-996-3423</phone>
      <email>nicholas.boice@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Kian Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center - Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benson Joseph</last_name>
      <phone>212-731-5076</phone>
      <email>Benson.Joseph@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>Chelsea Garcia</last_name>
      <phone>347-882-7907</phone>
      <email>Chelsea.Garcia@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Diane Simeone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evelyn H. Lauder Breast Center - Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amin Yaqubie</last_name>
      <phone>646-888-4327</phone>
      <email>yaqubiea@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Anna Varghese</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Physicians - Solid Tumor/Gastrointestinal Oncology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Machado</last_name>
      <phone>646-962-3378</phone>
      <email>sam4006@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Manuel Hidalgo Medina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-5127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheryl Foster</last_name>
      <phone>215-615-2220</phone>
      <email>sheryl.foster@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Beatty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asya Mascall</last_name>
      <phone>713-563-4799</phone>
      <email>anhayes@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Shubham Pant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Hospital &amp; Seattle Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pooja Rajeevan</last_name>
      <phone>206-287-6272</phone>
      <email>pooja.rajeevan@virginiamason.org</email>
    </contact>
    <contact_backup>
      <last_name>Janet Zaltsman</last_name>
      <email>janet.zaltsman@virginiamason.org</email>
    </contact_backup>
    <investigator>
      <last_name>Vincent Picozzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Samantha Elliot</last_name>
      <phone>206-606-6457</phone>
      <email>tellio@seattlecca.org</email>
    </contact>
    <contact_backup>
      <last_name>Susan Feldman</last_name>
      <phone>206-606-6457</phone>
      <email>sfeldman@seattlecca.org</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Coveler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

